Treatment of erectile dysfunction

被引:6
作者
Dinsmore, W [1 ]
机构
[1] Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland
关键词
erectile dysfunction; sildenafil; tadalafil; vardenafil; alprostadil; papaverine; phentolamine;
D O I
10.1258/095646204773557721
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Erectile dysfunction (ED) is an inability to attain or maintain an erection sufficient for satisfactory sexual intercourse. It is an undertreated and underdiagnosed condition that can be due to vasculogenic, neurogenic, hormonal and psychogenic factors. Effective treatment of ED should restore quality of life and allow patients to return to the sex life they had before. Current therapeutic options include non-pharmacological treatments, locally administered drugs and oral therapies. The oral phosphodiesterase-5 (PDE5) inhibitors are considered first-line treatments of ED and have revolutionized ED management in the last five years. Three PDE5 inhibitors are currently available, sildenafil, vardenafil and tadalafil. They are all effective with similar efficacy and good safety profiles. However, tadalafil has the added benefit of a broad window opportunity offering patients more freedom to choose when to initiate sexual activity.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 60 条
[21]   On life satisfaction in male erectile dysfunction [J].
FuglMeyer, AR ;
Lodnert, G ;
Branholm, IB ;
FuglMeyer, KS .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 1997, 9 (03) :141-148
[22]  
Gingell C, 1999, INT J CLIN PRACT, P30
[23]  
Giuliano F, 2002, EUR UROL SUPPL, V1, P1
[24]   Oral sildenafil in the treatment of erectile dysfunction [J].
Goldstein, I ;
Lue, TF ;
Padma-Nathan, H ;
Rosen, RC ;
Steers, WD ;
Wicker, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1397-1404
[25]   Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes - A multicenter double-blind placebo-controlled fixed-dose study [J].
Goldstein, I ;
Young, JM ;
Fischer, J ;
Bangerter, K ;
Segerson, T ;
Taylor, T .
DIABETES CARE, 2003, 26 (03) :777-783
[26]   Health outcomes variables important to patients in the treatment of erectile dysfunction [J].
Hanson-Divers, C ;
Jackson, SE ;
Lue, TF ;
Crawford, SY ;
Rosen, RC .
JOURNAL OF UROLOGY, 1998, 159 (05) :1541-1547
[27]   Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial [J].
Hellstrom, WJG ;
Gittelman, M ;
Karlin, G ;
Segerson, T ;
Thibonnier, M ;
Taylor, T ;
Padma-Nathan, H .
UROLOGY, 2003, 61 (04) :8-14
[28]  
Hellstrom WJG, 2002, J ANDROL, V23, P763
[29]   Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones [J].
Hellstrom, WJG ;
Overstreet, JW ;
Yu, A ;
Saikal, K ;
Shen, W ;
Beasley, CM ;
Watkins, VS .
JOURNAL OF UROLOGY, 2003, 170 (03) :887-891
[30]  
Jackson G, 2002, INT J CLIN PRACT, V56, P663